Clinical Trial Update: A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection [Phase 1]

View source ↗

Summary

A multicenter Phase I study of MRX34 liposomal injection (miR-34a mimic) across several cancers has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Lymphoma
• Melanoma
• Multiple Myeloma
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma
• Small Cell Lung Cancer

Drugs mentioned

• MRX34 liposomal injection (miR-34a mimic)

Snippet

Sponsor: Mirna Therapeutics, Inc. | Conditions: Primary Liver Cancer, SCLC | Phase 1 | Status: TERMINATED